Get the Stockscreener App
591.02
8.56%
46.61
After Hours:
593.00
1.98
+0.34%
Madrigal Pharmaceuticals Inc stock is traded at $591.02, with a volume of 966.78K.
It is up +8.56% in the last 24 hours and up +6.38% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$544.41
Open:
$552.42
24h Volume:
966.78K
Relative Volume:
2.78
Market Cap:
$13.42B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-23.53
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
+3.43%
1M Performance:
+6.38%
6M Performance:
+109.05%
1Y Performance:
+101.43%
1-Day Range:
$551.38
$593.59
1-Week Range:
$535.33
$593.59
52-Week Range:
$265.00
$605.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
591.02 | 12.36B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
(MDGL) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
Trend Report: How strong is Madrigal Pharmaceuticals Inc stock revenue growthQuarterly Profit Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade
Madrigal Pharmaceuticals Sees Bullish Price Target Increases Amid Market Excitement - timothysykes.com
What consensus target says about Madrigal Pharmaceuticals Inc. (YDO1) stockJuly 2025 Catalysts & Safe Capital Preservation Plans - ulpravda.ru
Madrigal Pharmaceuticals Sees Steady Surge with Revised Analyst Ratings - StocksToTrade
Madrigal Pharmaceuticals Sees Optimistic Price Target Upgrades Amid Expansion Expectations - StocksToTrade
Madrigal Pharmaceuticals’ Stock Surge: Analyzing Latest Price Target Upgrades - timothysykes.com
Madrigal Pharmaceuticals Sees Price Targets Raised Amid Rezdiffra Optimism - timothysykes.com
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge - Yahoo Finance
Piper Sandler Raises Price Target for MDGL to $900, Maintains Ov - GuruFocus
Piper Sandler raises Madrigal Pharmaceuticals stock price target to $900 on MASH opportunity - Investing.com UK
Will Madrigal Pharmaceuticals Inc. stock split attract more investorsGDP Growth & Free Community Consensus Stock Picks - DonanımHaber
Piper Sandler Raises Price Target for MDGL to $900, Maintains Overweight Rating | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. stock outperform value stocksRisk Management & Growth Oriented Trade Recommendations - DonanımHaber
Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler - TipRanks
Is Madrigal Pharmaceuticals Inc. stock a top momentum playMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
Madrigal Pharmaceuticals Inc (HAM:YDO1) Stock Earnings Transcripts - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals (HAM:YDO1) EV-to-OCF : -64.02 (As of Dec. 18, 2025) - GuruFocus
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Marex Group plc Buys New Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
2 Predictions for Novo Nordisk in 2026 - The Motley Fool
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockHigh Beta Stocks & High Return Capital Strategies - earlytimes.in
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells $10,297,597.50 in Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 24,800 Shares of Stock - MarketBeat
Braidwell LP Has $18.40 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Adage Capital Partners GP L.L.C. Buys 184,554 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Taub of Madrigal Pharmaceuticals sells $10.3 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) director sells after 24,800-share option - Stock Titan
Madrigal Pharmaceuticals (NASDAQ: MDGL) director discloses 10b5-1 sales, gift - Stock Titan
Madrigal Pharmaceuticals, Inc. $MDGL is Paulson & CO. Inc.'s Largest Position - MarketBeat
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Madrigal Pharmaceuticals Appoints New Chief Accounting Officer - TradingView
Key facts: B. Riley Raises Madrigal Price Target to $670; Directors File Form 144 - TradingView — Track All Markets
Check out Madrigal Pharmaceuticals's stock price (1MDGL-IT) in real time - CNBC
Madrigal Pharmaceuticals (MDGL) Sees Price Target Increase By B. - GuruFocus
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
HC Wainwright keeps buy on Madrigal Pharmaceuticals (MDGL) on strong Rezdiffra uptake and F2/F3 MASH patient data - MSN
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data - Insider Monkey
Invesco Ltd. Has $60.64 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Dir Taub Files To Sell 18,650 Of Madrigal Pharmaceuticals Inc [MDGL] - TradingView — Track All Markets
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Madrigal Pharmaceuticals Expands Workforce With New Equity Grants to Staff - MyChesCo
Madrigal Pharmaceuticals, Inc. $MDGL Holdings Increased by Stempoint Capital LP - MarketBeat
Marshall Wace LLP Acquires 52,319 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
Madrigal Pharmaceuticals moving to larger Montgomery County space as workforce balloons - The Business Journals
The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Two-Year Rezdiffra Cirrhosis Data - Sahm
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):